NCT00179712 2016-12-01Study of Lenalidomide With Topotecan In Subjects With Advanced Ovarian and Primary Peritoneal CarcinomaCelgene CorporationPhase 1/2 Completed60 enrolled
NCT00179725 2006-04-12Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid® CC-5013) With Liposomal Doxorubicin In Subjects With Advanced Ovarian and Primary Peritoneal CarcinomaCelgenePhase 1/2 Terminated60 enrolled